Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Viridian Therapeutics, Inc.\DE (VRDN) Gross Profit (2016)

Viridian Therapeutics, Inc.\DE (VRDN) has 3 years of Gross Profit data on record, last reported at $696000.0 in Q4 2016.

  • For Q4 2016, Gross Profit rose 202.05% year-over-year to $696000.0; the TTM value through Dec 2016 reached $1.8 million, up 898.9%, while the annual FY2016 figure was $1.7 million, 2427.27% up from the prior year.
  • Gross Profit reached $696000.0 in Q4 2016 per VRDN's latest filing, up from $337000.0 in the prior quarter.
  • Across five years, Gross Profit topped out at $2.3 million in Q3 2014 and bottomed at -$682000.0 in Q4 2015.
  • Average Gross Profit over 3 years is $547183.7, with a median of $387500.0 recorded in 2016.
  • Peak YoY movement for Gross Profit: plummeted 176.69% in 2015, then soared 557.14% in 2016.
  • A 3-year view of Gross Profit shows it stood at -$246484.0 in 2014, then tumbled by 176.69% to -$682000.0 in 2015, then surged by 202.05% to $696000.0 in 2016.
  • Per Business Quant database, its latest 3 readings for Gross Profit were $696000.0 in Q4 2016, $337000.0 in Q3 2016, and $368000.0 in Q2 2016.